Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Breast Neoplasms, Male 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × HER2 peptide (369-377) × Breast × Clear all
NCT02297698 2023-12-12

HER3+

Cancer Insight, LLC

Phase 2 Completed
100 enrolled 11 charts
Breast

Breast Neoplasms

NCT01570036 2020-12-02

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Cancer Insight, LLC

Phase 2 Completed
275 enrolled 23 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01479244 2017-02-27

PRESENT

Galena Biopharma, Inc.

Phase 3 Completed
758 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡